Michael J. Hafey

1.6k total citations · 1 hit paper
16 papers, 985 citations indexed

About

Michael J. Hafey is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Michael J. Hafey has authored 16 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pediatrics, Perinatology and Child Health and 5 papers in Pharmacology. Recurrent topics in Michael J. Hafey's work include Drug Transport and Resistance Mechanisms (12 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Drug-Induced Hepatotoxicity and Protection (4 papers). Michael J. Hafey is often cited by papers focused on Drug Transport and Resistance Mechanisms (12 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Drug-Induced Hepatotoxicity and Protection (4 papers). Michael J. Hafey collaborates with scholars based in United States, Canada and United Kingdom. Michael J. Hafey's co-authors include Maureen E. Murphy, Julia I-Ju Leu, Donna L. George, Patrick Dumont, Kelly Bleasby, Raymond Evers, Dennis Dean, Matthew P. Braun, Xiaoyan Chu and Shiyao Xu and has published in prestigious journals such as Nature Cell Biology, Journal of Pharmacology and Experimental Therapeutics and Clinical Pharmacology & Therapeutics.

In The Last Decade

Michael J. Hafey

16 papers receiving 964 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex

2004 627 citations Julia I-Ju Leu, Patrick Dumont et al. Nature Cell Biology profile →

Peers

Countries citing papers authored by Michael J. Hafey

Since Specialization

Citations

This map shows the geographic impact of Michael J. Hafey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Hafey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Hafey more than expected).

Fields of papers citing papers by Michael J. Hafey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Hafey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Hafey. The network helps show where Michael J. Hafey may publish in the future.

Co-authorship network of co-authors of Michael J. Hafey

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Hafey. A scholar is included among the top collaborators of Michael J. Hafey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Hafey. Michael J. Hafey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Transporters and Toxicity: Insights From the International Transporter Consortium Workshop 4 2022 ·Clinical Pharmacology & Therapeutics ·Michael J. Hafey, Lauren M. Aleksunes, Christy C. Bridges, Kenneth R. Brouwer, Huan‐Chieh Chien, Elaine M. Leslie, Shuiying Hu, Yang Li, (unknown), Alex Sparreboom, Jason A. Sprowl, Donald Tweedie, Yurong Lai	7
2	Physiologically-based modeling of cholate disposition in beagle dog with and without treatment of the liver transporter inhibitor simeprevir 2022 ·Computational Toxicology ·Shu‐Wen Teng, Michael J. Hafey, Jeanine Ballard, Xinjie Lin, (unknown), Vijay R. More, Robert Houle, (unknown), Ann Thomas, Grace Chan, (unknown), Yutai Li, Kara Pearson, Christopher R. Gibson	1
3	Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters 2021 ·Viruses ·Kelly Bleasby, Robert Houle, Michael J. Hafey, Meihong Lin, (unknown), Bing Lu, Rosa I. Sánchez, Kerry L. Fillgrove	17
4	A Two-Tiered In Vitro Approach to De-Risk Drug Candidates for Potential Bile Salt Export Pump Inhibition Liabilities in Drug Discovery 2020 ·Drug Metabolism and Disposition ·Michael J. Hafey, Robert Houle, Keith Q. Tanis, Ian Knemeyer, Jackie Shang, Qing Chen, Andreas R. Baudy, (unknown), Frank D. Sistare, Raymond Evers	14
5	Use of a Bile Salt Export Pump Knockdown Rat Susceptibility Model to Interrogate Mechanism of Drug-Induced Liver Toxicity 2019 ·Toxicological Sciences ·Yutai Li, Raymond Evers, Michael J. Hafey, (unknown), (unknown), (unknown), Lisa LaFranco-Scheuch, Stephen Pacchione, Alex M. Tamburino, Keith Q. Tanis, (unknown), Daniel Holder, (unknown), (unknown), Raymond J. Gonzalez, (unknown), Kara Pearson, José Antonio Lebrón, Warren E. Glaab, Frank D. Sistare	7
6	Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective 2018 ·Clinical Pharmacology & Therapeutics ·J. Gerry Kenna, Kunal S. Taskar, (unknown), David L. Bourdet, Kim L. R. Brouwer, Kenneth R. Brouwer, David L. Dai, Christoph Funk, Michael J. Hafey, Yurong Lai, Jonathan Maher, Y. Anne Pak, Jenny M. Pedersen, Joseph W. Polli, A. David Rodrigues, Paul B. Watkins, Kyunghee Yang, Robert W. Yucha	80
7	Antibiotic-induced Elevations of Plasma Bile Acids in Rats Independent of Bsep Inhibition 2017 ·Toxicological Sciences ·Yutai Li, Michael J. Hafey, (unknown), Raymond Evers, (unknown), Daniel Holder, (unknown), Frank D. Sistare, Warren E. Glaab	16
8	Design of Prodrugs to Enhance Colonic Absorption by Increasing Lipophilicity and Blocking Ionization 2014 ·Pharmaceuticals ·(unknown), Sophie‐Dorothée Clas, Rosa I. Sánchez, Abbas M. Walji, (unknown), (unknown), Jaume Balsells, (unknown), Qun Dang, David Jonathan Bennett, Michael J. Hafey, Junying Wang, John Higgins, Allen C. Templeton, Paul J. Coleman, Jay A. Grobler, Ronald L. Smith, Yunhui Wu	10
9	Design, Synthesis, and Evaluation of Prodrugs of Ertapenem 2013 ·ACS Medicinal Chemistry Letters ·Sheo B. Singh, Diane Rindgen, Prudence Bradley, L. D. Cama, Wanying Sun, Michael J. Hafey, Takao Suzuki, (unknown), Hao Wu, (unknown), Li Wang, (unknown), Hongshi Yu, Richard Söll, David B. Olsen, Peter T. Meinke, Deborah A. Nicoll‐Griffith	7
10	Nicotinic acids: Liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy 2011 ·Bioorganic & Medicinal Chemistry Letters ·David Powell, W. Cameron Black, Kelly Bleasby, Chi‐Chung Chan, Denis Deschênes, Marc Gagnon, (unknown), Jocelyne Guay, Sébastien Guiral, Michael J. Hafey, Zheng Huang, Élise Isabel, Yves Leblanc, Angela Styhler, Lijing Xu, Lei Zhang, Renata M. Oballa	15
11	Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents 2011 ·Bioorganic & Medicinal Chemistry Letters ·Jean-François Lévesque, Kelly Bleasby, Amandine Chefson, Austin Chen, Daniel Dubé, Yves Ducharme, (unknown), Sébastien Gagné, Michel Gallant, Erich L. Grimm, Michael J. Hafey, Yongxin Han, Robert Houle, (unknown), (unknown), Dwight Macdonald, Bruce Mackay, Robert Papp, Richard A. Tschirret-Guth	9
12	Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure 2009 ·Xenobiotica ·Huaibing He, Kathryn A. Lyons, Xiaofang Shen, (unknown), Kelly Bleasby, (unknown), Michael J. Hafey, (unknown), Shihao Xu, Gino Salituro, Leonard Cohen, Wei Tang	18
13	Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with anN-sulfonylated dipeptide VLA-4 antagonist in rats 2008 ·Xenobiotica ·Wei Tang, Ralph A. Stearns, Qing‐Hui Chen, Kelly Bleasby, Yohannes Teffera, Adria Colletti, Michael J. Hafey, Raymond Evers, Dennis Dean, Plato Α. Magriotis, Thomas J. Lanza, Liqing Lin, (unknown), Thomas A. Baillie	10
14	Transport of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin by Human Organic Anion Transporter 3, Organic Anion Transporting Polypeptide 4C1, and Multidrug Resistance P-glycoprotein 2007 ·Journal of Pharmacology and Experimental Therapeutics ·Xiaoyan Chu, Kelly Bleasby, Jocelyn Yabut, Xiaoxin Cai, Grace Chan, Michael J. Hafey, Shiyao Xu, Arthur Bergman, Matthew P. Braun, Dennis Dean, Raymond Evers	143
15	Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex breakdown → 2004 ·Nature Cell Biology ·Julia I-Ju Leu, Patrick Dumont, Michael J. Hafey, Maureen E. Murphy, Donna L. George	627
16	The Influence of Prior Thermal Treatments on Water Absorption by Wool 1974 ·Journal of the Textile Institute ·A.R. Haly, Michael J. Hafey	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact